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T-cell responses were detected by ex vivo ELISPOT in 
9/14 and 3/14 patients, respectively. A boost of pre-exist-
ing anti-FrC antibody (Ab) was detected by ELISA in 8/14 
patients, whilst anti-Id Ab was generated in 1/13 patients. 
Overall, four patients (29 %) made an immune response 
to FrC and Id, with six patients (43 %) responding to FrC 
alone. Over the 52-week study period, serum paraprotein 
was undetectable, decreased or remained stable for ten 
patients (71 %), whilst ongoing CR/PR was maintained for 
11 patients (79 %). The median time to progression was 
38.0 months for 13/14 patients. Overall survival was 64 % 
after a median follow-up of 85.6 months.
Keywords Multiple myeloma · Immunotherapy · Cancer 
vaccine · DNA vaccine · Idiotype
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Ab  Antibody
AE  Adverse event
ASCT  Autologous stem cell transplantation
BM  Bone marrow
CR  Complete response
FrC  Fragment C of tetanus toxin
HDT  High-dose chemotherapy
Abstract We report on the safety and immunogenicity of 
idiotypic DNA vaccination in a phase I, non-randomised, 
open-label study in patients with multiple myeloma. The 
study used DNA fusion gene vaccines encoding patient-
specific single chain variable fragment, or idiotype (Id), 
linked to fragment C (FrC) of tetanus toxin. Patients in 
complete or partial response following high-dose chemo-
therapy and autologous stem cell transplant were vacci-
nated intramuscularly with 1 mg DNA on six occasions, 
beginning at least 6 months post-transplant; follow-up was 
to week 52. Fourteen patients were enrolled on study and 
completed vaccinations. Idiotypic DNA vaccines were 
well tolerated with vaccine-related adverse events limited 
to low-grade constitutional symptoms. FrC- and Id-specific 
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Id  Idiotype
Ig  Immunoglobulin
MIATA  Minimal information about T-cell assays
MM  Multiple myeloma
OS  Overall survival
PBMC  Peripheral blood mononuclear cells
PR  Partial response
scFv  Single chain variable fragment
SD  Stable disease
SFC  Spot-forming cells
TTP  Time to progression
V genes  Variable region genes
VH  Heavy chain variable region gene
VL  Light chain variable region gene
Introduction
Multiple myeloma (MM) is a B-cell neoplasia characterised 
by the clonal proliferation of malignant plasma cells in the 
bone marrow (BM). Despite improved outcomes through 
novel treatments and autologous stem cell transplantation 
(ASCT) combined with high-dose chemotherapy (HDT), 
for most patients the disease remains incurable (www.can-
cer.org/cancer/multiplemyeloma/) [1, 2]. Current treatments 
are aimed at providing deep clinical responses alongside 
supportive care [3, 4]. The need for alternative therapeutic 
approaches is clear, in particular those that target and elimi-
nate minimal residual disease following ASCT, a scenario in 
which immunotherapy may prove valuable.
Malignant plasma cells secrete a monoclonal immu-
noglobulin (Ig), paraprotein, which can be detected in the 
serum and/or urine of patients. The monoclonal Ig expresses 
tumour-specific antigenic determinants called idiotopes, 
collectively termed idiotype (Id). Id are formed by the rear-
rangement of variable (V) region genes of the Ig heavy (VH) 
and light (VL) chains during B-cell maturation within the BM 
and subsequent somatic hypermutation within a germinal 
centre reaction following antigen encounter. Tumour-derived 
Id represents a tumour-specific antigen distinguishable from 
normal cells or plasma cells and, therefore, provides a unique 
target for immunotherapy [5, 6].
Prophylactic vaccination with tumour-derived Id has been 
shown to protect against subsequent tumour challenge in 
murine models of B-cell lymphoma and myeloma [7, 8]. Such 
data have led to clinical testing of idiotypic vaccines for the 
treatment of B-cell malignancies [9–11]; the most recent phase 
III study in follicular lymphoma demonstrated an increase in 
disease-free survival following vaccination with hybridoma-
derived Id [12]. However, in contrast to lymphoma where 
the Id is membrane bound, in MM Id is secreted, with little 
cell-surface expression [13]. Therefore, effective idiotypic 
vaccination in MM will require the induction of Id-specific T 
cells that are capable of recognising Id-derived peptides pre-
sented on MHC class I and class II molecules. Wen et al. [14] 
demonstrated that autologous Id-specific cytotoxic T cells of 
both CD8+ and CD4+ lineage generated from MM patients 
can lyse Id-pulsed autologous dendritic cells and autologous 
myeloma plasma cells, providing proof of concept, with the 
existence of cytotoxic CD4+ T cells increasingly recognised 
in recent decades [15]. Idiotypic vaccination in MM has been 
examined in clinical trials, where both humoral and cellular 
immunological responses have been reported; however, clini-
cal responses have been infrequent [10, 16–18].
Since Id is a self-protein, inducing sufficient immuno-
genicity is one challenge of vaccination. Our strategy uses a 
DNA fusion vaccine design to overcome the limited immu-
nogenicity of Id [19]. Patient-specific Id is firstly assembled 
as a single chain variable fragment (scFv) encoding the 
tumour-derived VH and VL region genes and next fused to 
fragment C (FrC) of tetanus toxin, an immune alert signal 
shown to significantly enhance the immunological response 
[7, 20, 21]. This DNA fusion vaccine design has distinct 
advantages as an immunotherapeutic strategy, including the 
ease of manufacture and administration, the engagement of 
diverse immune mechanisms to attack tumour cells, includ-
ing the innate system, and the capacity to overcome poten-
tial tolerance to the tumour [7, 19, 22].
Here, we present a phase I clinical trial using idiotypic 
DNA fusion vaccination in patients with MM and examine 
the safety and efficacy of this approach.
Materials and methods
The following materials and methods section is compli-
ant with minimal information about T-cell assay (MIATA) 
reporting (www.miataproject.org) [23]; further details are 
provided in Supplementary MIATA Information.
Patient cohort
Patients with newly diagnosed MM fulfilling WHO criteria, 
a performance status of ≤1 and who had received ASCT/
HDT in the first response were eligible [24]; patients with 
light chain only or non-secretory disease were excluded. 
The study was conducted in compliance with ICH-GCP 
and informed consent was provided by all participants fol-
lowing review and approval by the Medicines and Health-
care Regulatory Authority, the Gene Therapy Advisory 
Committee and the Local Research Ethics Committee.
Study design
The study was a phase I, non-randomised, open-label study 
of DNA vaccination without dose escalation. Patients 
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were vaccinated ≥6 months post-ASCT/HDT if a com-
plete or partial response (CR/PR) or stable disease (SD) 
was achieved [25]. One milligram of patient-specific scFv-
FrC DNA fusion vaccine was injected intramuscularly on 
6 occasions (week 0, 1, 2, 4, 8 and 12). On-study follow-
up was at weeks 0, 1, 2, 4, 8 and 12 following vaccination, 
monthly to week 32 and 3 monthly to week 52. Peripheral 
blood samples were collected for the evaluation of vaccine 
immunogenicity. Full blood count, serum biochemistry, 
paraprotein and beta-2 microglobulin analyses were per-
formed by the Department of Immunology, University Hos-
pital Southampton NHS Foundation Trust. Time to progres-
sion (TTP) and overall survival (OS) were recorded from 
the date of ASCT.
Patient material
An anti-coagulated BM aspirate was received fresh at 
diagnosis; mononuclear cells were separated by centrifu-
gation over lymphoprep™ (Axis-Shield PoC AS, Oslo, 
Norway) according to the manufacturer’s instructions. 
Viable cells were stored in liquid nitrogen in aliquots of 
5–10 × 106 cells/mL of freezing medium (10 % dimethyl-
sulphoxide, 50 % decomplemented human AB serum and 
40 % RPMI) until V gene identification. Pre-treatment 
serum (>10 mL) was harvested from clotted whole blood 
by centrifugation and stored in aliquots of 5 mL at −80 °C 
until paraprotein purification. Peripheral blood mononu-
clear cells (PBMCs) were isolated from on-study blood 
collections by centrifugation over lymphoprep™ (Axis-
Shield PoC AS) as described above; 5–10 × 106 viable 
cells/mL freezing medium were stored in liquid nitrogen. 
On-study serum was harvested by centrifugation and stored 
in aliquots of 1 mL at −80 °C.
Construction of patient‑specific scFv‑FrC DNA fusion 
vaccines
Procedures relating to the identification of tumour-derived 
V genes used in this study have been published previously 
[26]; total RNA was extracted from 5 to 10 × 106 tumour 
cells, followed by cDNA synthesis and PCR amplifica-
tion for VH and VL genes using standard primer combina-
tions and cycling conditions [20]. Tumour-related V genes 
were defined by the presence of repeated sequences with 
a clonally related complementarity determining region 3; 
sequence alignment analysis used MacVector software 
(Oxford Molecular, Oxford, UK) and aligned to the IMGT 
database (www.imgt.org). Tumour-derived VH and VL gene 
sequences were assembled as scFv, linked at the C-terminus 
to FrC and cloned into pcDNA3 vector (Invitrogen Limited, 
Paisley, UK) as previously described [7, 20]; vaccine design 
is shown in Supplementary Fig 1. Patient-specific vaccines 
were produced to GMP standard at NHS Blood and Trans-
plant, Clinical Biotechnology Centre, University of Bristol, 
and stored in sterile PBS at −80 °C until clinical use.
Generation of patient‑specific Id and FrC proteins 
for immunological endpoint evaluation
Assembly and expression of recombinant FrC and patient-
specific scFv proteins were as previously described [27]; 
FrC and scFv proteins were tagged at the C-terminus with 
kappa chain constant region and expressed using the mam-
malian FreeStyle™293 expression system (Invitrogen Ltd.) 
according to the manufacturer’s instructions. Purification of 
recombinant proteins used CaptureSelect® Fab kappa affin-
ity matrix (BAC B.V., Naarden, The Netherlands) accord-
ing to the manufacturer’s instructions. Tumour-derived 
scFv expression was successful in 11/14 patients; scFv 
protein was not available for immunomonitoring of patients 
MM08, MM10 and MM11.
Purification of paraprotein from patient serum used Cap-
tureSelect® human IgG affinity matrix and CaptureSelect® 
human IgA affinity matrix (BAC B.V.), for IgG (n = 8) and 
IgA (n = 5), respectively, according to the manufacturer’s 
instructions. Purification was not performed for IgD para-
protein (n = 1); paraprotein was not available for immuno-
monitoring of patient MM02.
Final protein concentration was determined by BCA™ 
protein assay (Perbio Science UK Ltd., Cramlington, UK). 
Size and purity was confirmed by separation by SDS-PAGE 
using NuPAGE bis–tris gradient polyacrylamide (4–12 %) 
gel (Invitrogen Ltd.) followed by staining with Simply-
Blue Safestain™ (Invitrogen Ltd.); western blot analysis 
using polyclonal goat anti-human kappa light chain HRP-
conjugated antibody (Ab) (Sigma-Aldrich Company Ltd.) 
was performed for recombinant scFv and FrC. Specificity of 
scFv was assessed by ELISA using patient-specific anti-Id 
Ab generated in C57BL/6 mice (n = 8–10) following vacci-
nation with scFv-FrC DNA vaccine, as previously described 
[7]; we previously showed anti-sera generated in this way is 
able to bind idiotypic Ig on the surface of autologous lym-
phoma cells, as measured by FACS analysis (unpublished 
observation). Specificity ELISA used polyclonal sheep 
anti-mouse IgG Ab (The Binding Site, Birmingham, UK) to 
detect the binding of patient-specific or non-specific control 
anti-sera to each protein. Endotoxin levels were assessed 
using the endpoint chromogenic (LAL) kit (Charles River 
Laboratories International, Inc., Wilmington, MA, USA) 
according to the manufacturer’s instructions.
Immunological evaluation
Ab responses to FrC were measured using a validated 
ELISA and quantified in relative Ab units against a tetanus 
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antitoxin human Ig reference standard (National Institute 
of Biological Standards and Control, UK), as previously 
described [28]. For the detection of anti-Id Ab, a 96-well 
Maxisorp immunoplate (Nunc, Roskilde, Denmark) was 
coated with 10 µg/mL patient-specific recombinant scFv 
protein or patient-purified IgA paraprotein; an irrelevant 
scFv/IgA paraprotein served as a negative control. Patient 
sera were tested at multiple time-points at a 1:10 dilu-
tion, with patient-specific mouse anti-sera used as a posi-
tive control (1:10). Specific anti-Id Ab was determined at 
each time-point by subtracting the mean absorbance of the 
irrelevant control protein from the test protein. All data are 
expressed as fold increase compared with pre-vaccination 
baseline (week 0). An antigen-specific response to the 
vaccine was defined as greater than or equal to twofold 
increase over pre-vaccination baseline at multiple time-
points [++] or a single time-point [+].
Cellular responses to the vaccine were measured on cry-
opreserved PBMCs by ex vivo IFN-γ (IL-13/IL-2) ELIS-
POT assay, as described previously [28]. PBMCs (4 × 105 
cells/well) were incubated with recombinant FrC (20 µg/
mL), recombinant scFv (100 µg/mL) and patient-purified 
paraprotein (100 µg/mL) for 40 h at 37 °C in 5 % CO2; 
control wells included an irrelevant scFv, an irrelevant 
isotype-matched paraprotein, medium only and phytohe-
magglutinin (PHA; 5 µg/mL; Sigma-Aldrich Company 
Ltd.). Spot-forming cells (SFC)/well were counted using 
the AID ELISpot Plate Reader System ELR04 and software 
(AutoImmun Diagnostika GmbH, Strassberg, Germany). 
Each well was first expressed as SFC/million PBMCs, fol-
lowed by subtracting the mean spot number of the tripli-
cate of unstimulated cells from the test triplicate [28, 29]; 
Id-specific responses were obtained by deducting spot val-
ues for irrelevant control proteins. A specific response to a 
test antigen at any given time-point was calculated as mean 
SFC/million minus mean SFC/million of pre-vaccination 
baseline and defined as ≥20 SFC/well and ≥2 SDEV 
above medium-only wells at multiple time-points [++] or 
a single time-point [+].
Clinical monitoring
TTP and OS were recorded to event or censor date for all 
patients on study; data were frozen in September 2013 
for analysis. TTP was defined as the time from the date of 
ASCT to progression of paraprotein, according to the Inter-
national Myeloma Working Group criteria [30]. OS was 
defined as the time from the date of ASCT to death.
Statistical analyses
Statistical analyses were performed with GraphPad Prism 
software, version 6.0a (GraphPad Software, Inc., La Jolla, 
USA). A significant antigen-specific response was deter-
mined by a Student’s t test with a confidence level of 95 % 
(P < 0.05). The distributions of time to event data were 
estimated using the Kaplan–Meier method and compared 
using the log-rank test statistic (Mantel–Cox).
Results
Patient characteristics
Following successful vaccine construction, 15 eligible 
patients were enrolled and received vaccination; one patient 
was removed from study after disease progression at week 
4 and is not included in safety and immunological analy-
ses. Patient MM19 exhibited slowly rising paraprotein at 
the week 0 visit (vaccination 1), but was otherwise in good 
general health with no clinical symptoms, and therefore 
the decision was taken to commence vaccination; sympto-
matic progression followed at week 43 and the patient was 
removed from study. Two further patients progressed post-
vaccinations and went off study at week 16 (MM04) and 
week 41 (MM10). The characteristics of 14 patients evalu-
able for vaccine safety and immunogenicity are shown in 
Table 1: ten patients were male; mean age was 58 years 
(range 36–70 years); 13 patients presented with Interna-
tional Staging System stage I or II disease [30]; Ig isotypes 
were IgG (n = 8), IgA (n = 5) and IgD (n = 1); CR, PR 
and SD were achieved in seven, six and one patients post-
ASCT/HDT, respectively; and mean time from ASCT to 
first vaccination was 12.5 months (range 6.4–21.4 months).
Safety and adverse events
The personalised idiotypic DNA fusion vaccines were safe 
and well tolerated (Table 2). Adverse event (AE) report-
ing was according to the Common Terminology Criteria 
for Adverse Events, version 4.03 (evs.nci.nih.gov). Eleven 
of 14 patients (79 %) reported AEs whilst on study. Five 
grade 3 AEs were reported, but were assessed as vaccine 
unrelated: pulmonary infection, chest pain, deep vein 
thrombosis, maculo-papular rash due to an allergic reaction 
and hospitalisation with head injury following a car acci-
dent. Vaccine-related AEs were grade 1 or 2 and consisted 
of constitutional symptoms, including flu-like symptoms 
(5/14 patients, 7 events), fatigue (4/14 patients, 7 events), 
musculoskeletal aches (5/14 patients, 7 events) and skin 
injection site reactions (2/14, 2 events).
Immunological evaluation
Serum and PBMCs were collected from each patient at 
defined time-points on study for subsequent immunological 
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analysis; immune responses were assessed by ELISA and 
ex vivo ELISPOT assay and are summarised in Table 3.
Ten of 14 patients (71 %) developed an immune response 
to FrC following vaccination (Table 3). Eight patients 
(57 %) boosted anti-FrC IgG Ab, of which seven exhibited 
a strong response [++]. Ab response kinetics are shown 
in Fig. 1a; the maximum response was 3.6-fold (week 15), 
3.0-fold (week 52), 3.8-fold (week 3), 3.6-fold (week 51), 
2.8-fold (week 8), 5.6-fold (week 29), 3.9-fold (week 17) 
and 5.1-fold (week 26) for MM01, MM03, MM04, MM05, 
MM11, MM17, MM19 and MM21, respectively. A FrC-
specific T-cell response was observed in 9 patients (64 %), 
of which four displayed a strong response [++] (Table 3; 
Fig. 1b).
Immune responses to Id were assessed against patient-
derived recombinant scFv protein and/or patient-purified 
paraprotein. We found no evidence for pre-existing Id-
specific cellular or humoral immune responses in any of 
the patients. Overall, 4/14 patients (29 %) developed an 
immune response to Id (Table 3). Anti-Id IgG ELISA was 
performed for 13/14 patients against either recombinant 
scFv protein (n = 9), IgA paraprotein (n = 2) or both 
(n = 2). Following vaccination, 1/13 patients (8 %; MM19) 
generated an anti-Id IgG Ab response [++] detectable with 
recombinant scFv, the kinetics of which paralleled that to 
FrC; the maximum anti-Id response was 10.5-fold (week 
8), and anti-Id Ab was maintained for the length of the 
study (Fig. 1c). No anti-Id IgG Ab response was observed 
when assayed with patient-purified IgA paraprotein. 
Anti-Id ELISPOT was performed for all patients against 
either recombinant scFv protein (n = 1), Ig paraprotein 
(n = 4) or both (n = 9). Three of 14 patients (21 %) devel-
oped an Id-specific T-cell response following vaccination 
(Table 3; Fig. 1d); in each case, a FrC-specific humoral 
and/or cellular response was also observed. Two patients 
(MM01 and MM07) demonstrated anti-Id T cells [+] upon 
stimulation with patient-purified IgG paraprotein, but not 
recombinant scFv in the case of MM07; due to limited 
PBMCs, ELISPOT was not performed against recombinant 
scFv for patient MM01. Conversely, patient MM05 exhib-
ited a strong T-cell response [++] to recombinant scFv, 
but not patient-purified IgG paraprotein, with a maximum 
increase in IFN-γ and IL-13 production of 4.8-fold and 2.8-
fold, respectively (week 3); no IL-2 secretion was observed 
(Fig. 1e). The response to scFv paralleled that to FrC.
Clinical outcome
Serum paraprotein was undetectable in eight patients at the 
onset of vaccination (week 0) and remained so for the full 
52-week study period in seven patients (50 %). The con-
centration of paraprotein at pre-vaccination baseline ranged 
from 2.0 to 26.0 g/L (mean 8.8 g/L; n = 6). Figure 2 shows 
the change in paraprotein concentration for all patients in 
which paraprotein was detectable at any point during the 
study (n = 7), including the four Id responders: MM01, 
MM05, MM07 and MM19. One patient (7 %; MM01) 
exhibited a decrease in serum paraprotein by 8.9 g/L, whilst 
Table 1  Patient characteristics
CTD cyclophosphamide/thalidomide/dexamethasone, C-VAD cyclophosphamide/vincristine/adriamycin/dexamethasone, M melphalan, RT radi-
otherapy, VAD vincristine/adriamycin/dexamethasone, T thalidomide maintenance
a Staging of disease used the International Staging System introduced by the International Myeloma Working Group [30]
b Status of disease post-ASCT/HDT: complete response (CR), partial response (PR), stable disease (SD)
Patient Sex/age Id isotype Disease  
stagea
Prior therapies Disease  
statusb
Time from ASCT to 
vaccination (months)
MM01 M/64 IgG/K II RT, 4xVAD PR 9.9
MM02 M/70 IgD/K I 5xC-VAD CR 7.6
MM03 M/66 IgG/K II 6xC-VAD PR 13.6
MM04 M/69 IgG/L I 4xCTD PR 16.5
MM05 F/65 IgG/K II 4xCTD PR 6.5
MM07 F/42 IgG/L II 6xCTD SD 9.4
MM08 M/64 IgG/K II 6xVAD CR 9.9
MM09 M/66 IgG/K I 6xCTD PR 9.2
MM10 F/36 IgA/K II 5xCTD CR 10.8
MM11 M/51 IgA/K II 5xCTD CR 6.4
MM15 F/59 IgA/L I 5xCTD CR 19.0
MM17 M/45 IgG/K I 5xCTD CR 21.4
MM19 M/62 IgA/L II 6xC-VAD, 1xM CR 15.4
MM21 M/54 IgA/K II/III 6xCTD, 1xM, T PR 18.7
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paraprotein remained stable, with some minor fluctuations 
(<1.0 g/L), in two patients (14 %; MM05 and MM21). In 
four patients (29 %), serum paraprotein increased (mean 
11.4 g/L, range 5.9–21.8 g/L), with three patients removed 
from study due to disease progression: MM04 at week 16 
(IgG paraprotein increase of 11.6 g/L plus clinical pro-
gression), MM10 at week 41 (IgA paraprotein increase of 
6.4 g/L, asymptomatic) and MM19 at week 43 (IgA para-
protein increase of 21.8 g/L plus clinical progression).
TTP and OS were assessed and recorded for all patients 
(Table 3; Supplementary Fig 2). By the end of on-study 
follow-up, 11 patients (79 %) remained in ongoing CR/
PR, which decreased to one patient (7 %) by the censor 
date; post-ASCT/HDT, ongoing CR/PR was maintained 
for 3+ years in eight patients (57 %), for 4+ years in five 
patients (36 %) and for 5+ years in two patients (14 %). 
Median TTP was 38.0 months for 13/14 patients; median 
TTP was 27.0 months for Id responders (n = 4) compared 
with 45.0 months for Id non-responders (n = 9) (Supple-
mentary Fig 2a; log-rank P value = 0.206). OS was 64 % 
(9/14 patients) after a median follow-up of 85.6 months 
(range 34.7–106.5 months), with all deaths due to end stage 
MM; there was no significant difference in OS between Id 
responders and Id non-responders (Supplementary Fig 2b; 
log-rank P value = 0.430).
Discussion
The present phase I clinical trial employed patient-spe-
cific DNA fusion vaccination to target MM; vaccines 
were composed of tumour-derived scFv linked to FrC of 
tetanus toxin, which has previously shown to enhance 
the immune response to Id [7, 20, 21]. Individual scFv-
FrC DNA fusion vaccines were constructed and safely 
delivered to 14 patients with myeloma following treat-
ment with ASCT/HDT; no vaccine-related AEs of grade 
3 or above were observed. Vaccine-induced immune 
responses were examined: 71 and 29 % of patients gener-
ated responses to FrC and Id, respectively. The majority 
of patients maintained favourable serum paraprotein lev-
els (71 %) and upheld ongoing CR/PR (79 %) during the 
52-week study period. Median TTP was 38.0 months for 
13 patients, and OS was 64 % after a median follow-up of 
85.6 months.
Table 2  Adverse events
Adverse eventa Grade 1 Grade 2 Grade 3
Cardiac disorders
 Chest pain 1 (1.6 %)
 Tachycardia 1 (1.6 %)
Gastrointestinal
 Abdominal pain 2 (3.2 %)
 Diarrhoea 1 (1.6 %)
 Dyspepsia 1 (1.6 %)
 Nausea 1 (1.6 %)
 Periodontal disease—gingivitis 1 (1.6 %)
 Vomiting 2 (3.2 %)
General disorders and administration site reactions
 Oedema—limb 1 (1.2 %)
 Fatigue 7 (11.3 %)
 Fever 1 (1.6 %) 1 (1.6 %)
 Flu-like symptoms 6 (9.7 %) 1 (1.6 %)
 Injection site redness, rash 2 (3.2 %)
 Other, diaphoresis 1 (1.6 %)
Infections and infestations
 Eye 1 (1.6 %)
 Lung 1 (1.6 %)
 Upper respiratory 3 (4.8 %) 1 (1.6 %)
 Other, varicella zoster virus 1 (1.6 %)
Metabolism and nutrition disorder
 Anorexia 1 (1.6 %)
Musculoskeletal and connective tissue disorders
 Arthralgia 1 (1.6 %)
 Arthritis 1 (1.6 %)
 Back pain 1 (1.6 %)
 Chest wall pain 1 (1.6 %)
 Myalgia 2 (3.2 %)
 Shoulder pain 1 (1.6 %)
Nervous system disorders
 Lethargy 1 (1.6 %)
 Neuralgia 1 (1.6 %)
Psychiatric disorders
 Confusion 1 (1.6 %)
 Depression 1 (1.6 %)
Respiratory, thoracic and mediastinal disorders
 Cough 3 (4.8 %)
 Pharyngolaryngeal pain 3 (4.8 %)
 Pleuritic pain 1 (1.6 %)
Skin and subcutaneous tissue disorders
 Pruritus 1 (1.6 %)
 Rash maculo-papular 1 (1.6 %) 1 (1.6 %)
Social circumstances
 Social circumstances—other 1 (1.6 %)
Vascular disorders
 Hypertension 1 (1.6 %)
a Recording of adverse events used the Common Terminology Crite-
ria for Adverse Events, version 4.03
Table 2  continued
Adverse eventa Grade 1 Grade 2 Grade 3
 Thromboembolic event 1 (1.6 %)
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Patients with MM have a decreased ability to mount 
a response to vaccination due to widespread immuno-
suppressive treatment regimens [31]. In 29 % of our 
patients, vaccination failed to provoke a cellular or 
humoral response to the immune alert signal FrC, sug-
gestive of persistent immunodeficiency since vaccine 
delivery was not compromised at any time. Vaccination 
was initiated ≥6 months post-ASCT/HDT. We have pre-
viously shown that MM patients demonstrate substantial 
recovery of responsiveness to tetanus toxin vaccination 
within 6 months–1 year following treatment [32]. In this 
period, myeloma burden is predicted to be at its low-
est and immune reconstitution to be well advanced [25]. 
Moreover, low disease burden is known to be associated 
with augmented responses to anti-tumour vaccination 
[33]. The recovery of immune competence is evident from 
a successful expansion of FrC-specific immune responses 
in 71 %; mean time between ASCT/HDT and vaccination 
for FrC responders and FrC non-responders was not sig-
nificantly different at 12.9 and 11.4 months, respectively 
(P value = 0.474).
Overall, our DNA fusion vaccine approach resulted in 
the generation of Id-specific immune responses in 29 % 
of patients, detectable in peripheral blood; we believe 
that this is a clinically relevant response rate as published 
data show that numbers of Id-specific T cells occur in the 
blood and BM at a similar frequency [34]. Our vaccine 
was designed to provide CD4+ T-cell help through the 
FrC component [7], as well as activate the innate immune 
system through the plasmid backbone. We show that the 
anti-Id responses achieved are comparable to those gen-
erated in MM patients vaccinated against influenza virus, 
which have been reported to be as low as 19 % [35]. We 
report vaccine-induced anti-Id Ab for one patient despite 
a rising paraprotein sufficient to require further treatment 
and early removal from the study. Since myeloma cells 
secrete tumour-specific monoclonal Ig, it is traditionally 
considered that anti-Id Ab is not effective against plasma 
tumour cells because (1) the large amount of circulating 
soluble paraprotein may bind and neutralise the anti-Id Ab 
and (2) the absence of surface Ig on tumour cells renders 
them resistant to the effect of anti-Id Ab. Yet, Moshitzky 
Table 3  Summary of immune responses and clinical outcome
na not assayed
a Positive immune response criteria: for ELISA, greater than or equal to twofold increase over pre-vaccination baseline at multiple time-points 
(++) or a single time-point (+); for ELISPOT, mean SFC minus baseline SFC of ≥20 SFC/well and ≥2 SD above medium-only wells at multi-
ple time-points (++) or a single time-point (+)
b Immune responses were assayed using patient-purified paraprotein (P) and/or patient-derived recombinant scFv (S)
c TTP was defined as the time from the date of ASCT to progression of paraprotein, according to the International Myeloma Working Group 
criteria [30] or to the point of data censor (September 2013): +CR maintained
d OS was defined as the time from the date of ASCT to death or to the point of data censor (September. 2013): +alive
Patient Immune responsesa Clinical outcome
FrC-specific Id-specificb TTPc (months) OSd (months)
Humoral Cellular Humoral Cellular
MM01 ++ ++ −S +P 32.9 45.8
MM02 − − −S −S 56.0 96.1+
MM03 + ++ −S −S,P 48.0 98.8
MM04 ++ + −S −S,P 19.5 49.4
MM05 ++ ++ −S ++S, −P 50.5 106.5+
MM07 − + −S −S, +P 21.0 92.1+
MM08 − − na −P 64.4 105.5+
MM09 − − −S −S,P 38.0 102.0+
MM10 − + −P −P 14.7 37.7
MM11 ++ + −P −P 46.0 79.0+
MM15 − − −S,P −S,P 95.1+ 95.1+
MM17 ++ + −S −S,P 35.0 65.1+
MM19 ++ − ++S, −P −S,P 15.4 34.7
MM21 ++ ++ −S −S,P 45.0 45.0+
Total immune responses 8/14 9/14 1/13 3/14
10/14 4/14
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(a) (b)
(c)
(e)
(d)
Fig. 1  Vaccine-induced immune responses. Following vaccination 
with scFv-FrC DNA fusion vaccine, humoral and cellular immune 
responses to both FrC and Id were monitored in the blood of patients 
at regular time-points over the 52-week study period; detection was 
by ELISA and ex vivo IFN-γ ELISPOT, respectively, and the criteria 
for positive responses are as described in the “Materials and meth-
ods” section and Supplementary MIATA Information. a Eight of 14 
patients generated a boost in anti-FrC IgG Ab following vaccination; 
MM01 (closed circles), MM03 (closed squares), MM04 (closed tri-
angles), MM05 (closed diamonds), MM11 (open circles), MM17 
(open squares), MM19 (open triangles) and MM21 (open diamonds). 
Data are expressed as fold increase over pre-vaccination baseline. 
Patient MM17 received a tetanus booster vaccination at week 25 
on study as part of routine vaccinations for travel purposes, as indi-
cated by a dashed line. b Nine of 14 patients developed a FrC-spe-
cific T-cell response following vaccination; MM01 (closed circles), 
MM03 (closed squares), MM04 (closed triangles), MM05 (closed 
diamonds), MM07 (open circles), MM10 (open squares), MM11 
(open triangles), MM17 (open diamonds) and MM21 (closed stars). 
c One of 13 patients (MM19) generated an anti-Id IgG Ab response 
following vaccination, detectable against scFv (closed circles), but 
not paraprotein (open circles). An irrelevant scFv target derived from 
patient MM05 was used to establish the specificity of the response. 
The FrC-specific IgG Ab response for this patient is shown for com-
parison (closed squares). Data are expressed as fold increase over 
pre-vaccination baseline. d Three of 14 patients developed an Id-
specific T-cell response following vaccination, which was directed 
against either scFv (n = 1; closed symbols) or Ig paraprotein (n = 2; 
open symbols); MM01 (circles), MM05 (squares) and MM07 (trian-
gles). e Id-specific T cells generated following vaccination in patient 
MM05 secreted IFN-γ (closed circles) and IL-13 (closed squares), 
but not IL-2 (closed triangles), upon stimulation with scFv; stimula-
tion with an irrelevant scFv target derived from patient MM09 was 
used to establish specificity of the response. The FrC-specific T-cell 
response (IFN-γ-release) for this patient is shown for comparison 
(open circles)
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et al. [36] demonstrate that anti-Id Ab is capable of inhib-
iting the growth of myeloma cells in the absence of mem-
brane-bound Ig in the murine D2 plasmacytoma model 
suggesting anti-Id Ab could confer clinical benefit. Whilst 
we previously demonstrated that anti-sera generated in 
mice following immunisation with scFv can recognise 
autologous Ig (using low-grade non-Hodgkin lymphoma 
sequences as the source of idiotypic protein-unpublished 
observations), our data here suggest there may be a dif-
ference between recognition of whole Ig and scFv, since 
scFv is seen but not paraprotein. This may be due to dif-
ferences in protein folding, with novel, immunogenetic 
B-cell epitopes revealed in scFv that are not visible on the 
human paraprotein.
The development of an anti-Id cellular immune 
response is believed to be of greatest importance for the 
effective treatment of MM; the lysis of autologous mye-
loma plasma cells by Id-specific T cells [14] and a cor-
relation between vaccine-induced Id-specific T cells and 
a reduction in circulating myeloma cells in patients [37] 
have been demonstrated. We report vaccine-induced anti-
Id T-cell responses for three patients, detectable with 
either scFv (n = 1) or paraprotein (n = 2). Pre-clinically, 
using the murine MOPC-315 plasmacytoma model, 
Fig. 2  Serum paraprotein. The concentration of serum paraprotein 
(g/L) was monitored at regular time-points over the 52-week study 
period for all patients; 7/14 patients displayed detectable paraprotein 
during the study period. Serum paraprotein decreased or remained 
stable for one and two patients, respectively. Four patients exhibited 
rising paraprotein, which was indicative of disease progression in 
three patients who were subsequently removed from study before the 
completion of follow-up, as indicated by an asterisk: MM04 (week 
16), MM10 (week 41) and MM19 (week 43). Closed circles represent 
Id responders (n = 4) and open circles represent Id non-responders 
(n = 3). Serum protein electrophoresis was performed by the Depart-
ment of Immunology, University Hospital Southampton NHS Foun-
dation Trust
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Bogen et al. [38] demonstrated that vaccine-induced 
T-cell responses to an Id of the myeloma protein M315 
were heavily influenced by the quaternary structure of 
the stimulating protein in a proliferation assay, with a 
100-fold to 1000-fold higher molar concentration of Fab 
or whole IgA needed to induce equivalent responses to 
Fv, suggesting that whole Ig is poorly processed in vitro, 
and possible in vivo, which may explain the relatively 
low frequency of anti-Id responses observed. These data 
may also be relevant for understanding the differential Ab 
responses to scFv and paraprotein noted earlier. Naturally 
occurring Id-specific CD4+ T cells have been detected by 
proliferation and/or ELISPOT assay in the blood of pre-
viously untreated MM patients with stage I or II disease 
[18, 39]. Hansson et al. [18] report that Id-specific T cells 
were associated with patients with serum paraprotein of 
below 50 g/L, indicating that idiotypic vaccination may 
be more relevant for patients with a low tumour burden. 
Patients with pre-existing anti-Id T cells may respond 
better to vaccination as it may be easier to boost rather 
than induce de novo immunity against weak self-antigens. 
Indeed, vaccine-induced Id-specific T-cell responses are 
more frequently reported in patients that exhibit a pre-
existing anti-Id T-cell pool [18, 40]. In our study, we 
did not observed any pre-existing Id-specific cellular 
immune responses although all patients had serum para-
protein of <50 g/L, suggesting that vaccination stimulates 
a new pool of T cells against Id. The hurdle for prim-
ing an immune response to Id is probably much greater 
than that for a recall response; this likely contributes to 
the difference in magnitudes between anti-FrC and anti-
Id responses. However, it is important to remember that 
in our study patients had previously received ASCT/HDT 
and were 6.4–21.4 months post-therapy.
Clinical trials employing idiotypic vaccination have 
shown mixed responses in follicular lymphoma and MM 
thus far [9–12]. Recent trials of idiotypic vaccination in 
MM have used Id protein coupled to immunogenic car-
riers, such as key hole limpet haemocyanin and filamen-
tous phage, in combination with adjuvant cytokines (GM-
CSF and IL-12) and Id-pulsed dendritic cells amongst 
others, and have shown that Id-specific T-cell responses 
can be generated in approximately 50 % of patients 
[40, 41]. Conversely, clinical responses were observed 
in only 12 % of patients, demonstrating that Id-specific 
responses do not always give rise to clinical benefit. We 
demonstrate that Id-specific T cells are associated with a 
reduction in serum paraprotein in one patient. Although 
we cannot definitively conclude that the presence of Id-
specific T cells is causative, this is highly implied in the 
absence of further clinical intervention. Increases in Id-
specific T cells can correlate with reduced numbers of 
circulating myeloma cells, even without a reduction in 
serum paraprotein or evidence for a survival benefit [37]. 
Conversely, clinical responses have been seen without the 
induction of measurable immune responses [40]. Overall 
in our study, the stabilisation or decrease in paraprotein 
in MM patients following idiotypic vaccination is encour-
aging, but since patients had previously received ASCT/
HDT it is difficult to dissect the effects of the vaccine 
from that of a delayed response to treatment and, there-
fore, they must be interpreted with caution.
Improved immunotherapeutics for myeloma are clearly 
needed. One option would be to use a generic target for 
DNA fusion vaccination, such as CS1, CD38 or CD138 
[42], to avoid the need for bespoke vaccine production. A 
second approach could be to increase vaccine efficiency by 
delivery of DNA vaccine with electroporation, which has 
previously shown to amplify immune responses induced 
by therapeutic cancer vaccines [43]. Recent data indicate 
that deep and prolonged clinical responses can be achieved 
using the immunomodulatory drug lenalidomide as part of 
induction pre-ASCT and maintenance therapy [44]. Given 
that lenalidomide has also been demonstrated to augment 
responses to pneumococcal vaccination through its immu-
nomodulatory effects, a combination approach using Id 
vaccination alongside immunomodulatory agents is attrac-
tive [45]. Our data will be useful for the design of clini-
cal trials powered to assess effect of idiotypic vaccination 
on improving clinical endpoints, with the hope of devel-
oping a therapeutic vaccination strategy to delay disease 
progression.
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